Vectura earns $11m milestone with Hikma generic launch

Published: 18-Dec-2020
Regulatory Drug Delivery

The launch of the product follows approval by the US FDA

Vectura Group partner Hikma Pharmaceuticals has launched its generic version of GlaxoSmithKline’s Advair Diskus (fluticasone propionate and salmeterol inhalation powder), 100 mcg/50 mcg and 250 mcg/50 mcg doses, in the US.

As a result of the product’s FDA approval, Vectura will receive a payment of $11m which will be recognised in 2020, and will earn a mid-teen royalty on net sales of the product.

Hikma’s powder is indicated for the treatment of asthma, the maintenance treatment of airflow obstruction, and for reducing exacerbations in patients with chronic obstructive pulmonary disease. It’s delivered using Vectura’s proprietary lever-operated multi-dose inhaler device technology.

This marks the first US FDA approval of a Vectura dry powder inhaler and joins Vectura’s portfolio of approved inhalation devices in Europe and globally, such as GyroHaler and FOX.

Will Downie, CEO of Vectura, said, “This is excellent news for Vectura and for people living with asthma and COPD in the US. Approval of this high quality substitutable generic product for Advair Diskus validates Vectura’s rare, industry-leading development capabilities and the strong partnership we have with Hikma. Approval of this product paves the way for our substitutable drug-device combination programme, also partnered with Hikma, for generic versions of the GSK Ellipta portfolio, in the coming years.”

  • Companies:
  • Vectura Group
See more

You may also like

Drug Delivery

Vectura’s $62.7m inhalation centre granted planning permission

Read more
The state-of-the-art building is set to be completed in 2025 and will enable Vectura to expand its operations

Trending Articles

  1. Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for successful market entry from the early stages of development, reports Frederick Duynslaeger, Senior CMC Writer at Ardena
  2. Overcoming CMC challenges in cell and gene therapy: part I Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
  3. Overcoming CMC challenges in cell and gene therapy: part II Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
  4. OINDPs: Nosey about recent developments? OINDPs are a user friendly and efficacious alternative to injectables in several disease areas
  5. The significance of the perfect gelatin in softgel production Capsule dosage forms, including soft gelatin capsules, continue to experience growing popularity throughout the pharmaceutical and nutraceutical market because of their advantages compared with other delivery forms

Upcoming event

Cleanroom Conference UK

22–23 May 2024 | Exhibition | Birmingham, UK See all

You may also like

Drug Delivery

Vectura’s $62.7m inhalation centre granted planning permission

The state-of-the-art building is set to be completed in 2025 and will enable Vectura to expand its operations
Drug Delivery

Optimising dry powder inhaler programmes through formulation

The use of dry powder formulations originally focused on respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD) because pulmonary administration of the active pharmaceutical ingredient (API) provides direct and rapid action. However, direct delivery to the lung is also a quick and efficient way of administering non-respiratory drugs systemically without have to wait for them to be absorbed through the gut
Ingredients

Accelerating excipient development for inhalable dosage forms with QbD

Whether they are simply giving an oral dose the bulk it needs to permit handling and swallowing or performing more complex functions that enable successful delivery and product performance, excipients are critical components of all drug formulations, explains Iain Davidson, Senior Manager, Pharmaceutical Development, Vectura
Regulatory

Status update on ANDA for generic Advair Diskus (VR315 [US])

Vectura Group, an industry leading inhalation CDMO, confirms the announcement made by its partner Hikma Pharmaceuticals
Drug Delivery

Hikma announces agreement with Vectura to develop generic salmeterol for the US market

Hikma is a fast-growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products
Drug Delivery

Vectura and Propeller Health link up to develop digitally-connected inhalers for chronic respiratory diseases

The two firms are also discussing additional connected strategies for other proprietary respiratory devices in Vectura’s pipeline
Regulatory

Recipharm provides access to dossier for Asmasal Clickhaler Chinese market approval

Regulatory submission will be led by Vectura’s new strategic joint venture , Tianjin Kinnovata; collaboration will see Recipharm manufacturing finished product for Kinnovata and the Chinese market
Subscribe now